Wanbury receives renewed USFDA approval for Patalganga plant

New Delhi, Aug 20 (UNI) Wanbury Ltd has said the United States Food and Drug Administration (USFDA) has renewed its approval for the company's multi-product Active Pharmaceutical Ingredients (API) facility at Patalganga, Maharashtra.

The company will manufacture three new products namely Tramadol, Amytriptyline and Paroxetine at this plant.

The USFDA approval for the Patalganga Plant was received earlier in 2002.

The plant will continue to manufacture existing products like Metformin and Salsalate, a company statement said.

UNI CS PV HT1245